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https://doi.org/10.101The myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal neoplas-
tic disorders. Driver mutations in JAK2, CALR, and MPL genes have been identified in
the majority of cases. Alongside these, an increasing number of genes are repeatedly
identified as mutated in MPN. These, including ASXL1, TET2, DMNT3A, and EZH2,
have key roles in epigenetic regulation. Dysregulation of epigenetic processes is there-
fore a key feature of MPN. Vorinostat is a pan histone deacetylase inhibitor (HDACi)
that has been investigated in MPN. DNA methylation (DNAm) is a well-defined epige-
netic mechanism of transcription modification. It is known to be affected by ageing,
lifestyle, and disease. Epigenetic ageing signatures have been previously described
allowing calculation of a methylation age (MA). In this study we examined the effect of
vorinostat on MA in MPN cell lines and in patients with polycythaemia vera (PV) and
essential thrombocythaemia (ET) treated with vorinostat as part of a clinical trial. An
older MA was observed in patients with a higher JAK2 V617F allele burden and those
with a longer duration of disease. PV patients had a MA older than that predicted
whilst MA was younger than predicted in ET. Treatment with vorinostat resulted in a
younger MA in PV patients and older MA in ET patients, in both cases a trend
towards the normal chronological age. When MA change was compared against
response, nonresponse was associated with a younger than predicted MA in ET patients
and a higher than predicted MA in PV patients. The link between MA and JAK2
mutant allele burden implies that allele burden has a role not only in clinical pheno-
type and disease evolution in MPN patients, but also in the overall methylation land-
scape of the mutated cells. © 2019 ISEH – Society for Hematology and Stem Cells.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)The myeloproliferative neoplasms (MPNs) are a group
of clonal hematological disorders in which there is a
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6/j.exphem.2019.09.025health to an abnormal monoclonal proliferation of
blood cells. Polycythemia vera (PV) and essential
thrombocythemia (ET) are characterized by the excess
production of red blood cells and platelets, respec-
tively. Identification of the JAK2 V617F driver muta-
tion, in 95% of PV cases and 50% of ET cases,
causing constitutive activation of the JAK/STATd by Elsevier Inc. This is an open access article under the CC BY-NC-
S. McPherson et al. / Experimental Hematology 2019;79:26−34 27pathway has revolutionized our understanding of the
pathogenesis of these conditions [1]. In JAK2 V617F-
negative cases, driver mutations in MPL and CALR
have been identified in the majority of remaining ET
cases [2,3]. There is now evidence that MPNs are the
result of combined genetic and epigenetic dysregula-
tion, with mutations in cooperating genes increasingly
reported [4]. These include genes involved in cell sig-
nalling pathways (LNK, CBL, NRA, NF1), epigenetic
regulation (ASXL1, EZH2, TET2, DNMT3A, IDH1,
IDH2), transcriptional regulation (TP53, RUNX1), and
mRNA processing (SF3B1, SRSF2, U2AF1, ZRSR2).
These mutations dictate the way genes are expressed,
and are not MPN specific, being found in a wide vari-
ety of myeloid disease phenotypes and clonal hemato-
poiesis of indeterminate potential [5]. In addition, they
are not mutually exclusive, making the hierarchy com-
plex and unpredictable. Increasing evidence suggests
that the order of acquisition of mutations can determine
the phenotype of the disease [6]. Other mechanisms of
epigenetic dysregulation have been identified in MPN.
JAK2 V617F protein localises to the nucleus mediating
phosphorylation of histone H3 and the arginine methyl-
transferase PRMT5 [7,8]. Overexpression of the tran-
scription factor in NFE2 in PV results in elevated
levels of JMJD1C, a histone demethylase, and subse-
quent global reductions in H3K9me1 and H3K9me2
levels [9]. In addition, DNA methylation patterns have
been reported to be abnormal in chronic-phase MPN
and change further in transformation to blast-phase
disease [10].
Best available therapies (BATs) have remained
unchanged for PV and ET patients for many years and
include low-dose aspirin and cytoreductive agents such
as hydroxycarbamide. These therapies have no effect
on modifying the underlying disease process. Recent
developments include the use of specific JAK inhibitors
including ruxolitinib, a direct JAK1 and JAK2 inhibi-
tor. Studies have indicated improved hematocrit con-
trol, spleen volume reduction, and modest but
sustained allele burden reduction in PV patients resis-
tant or intolerant to HU [11,12]. However, no benefit
over BATs was established for ET in the same second-
line setting [13]. As the role of epigenetic dysregula-
tion in MPN becomes increasingly established, epige-
netic therapies have been trialed in MPN. Vorinostat
(MK-0683) is a pan histone deacetylase inhibitor (HDACi)
which has been reported to induce tumour cells to undergo
growth arrest, differentiation, or apoptotic cell death [14
−16]. In PV and ET, vorinostat has demonstrated efficacy
in MPN. Discontinuation of therapy over a 6-month treat-
ment phase was high, with only 48% of patients complet-
ing the treatment course. A majority of patients had
decreased leucocyte or platelet counts on treatment, with a
reduction in the prevalence of splenomegaly and pruritusobserved. Very modest reductions in the JAK2 V617F bur-
den in positive patients were observed with no relation to
response [17].
DNA methylation (DNAm) is known to be altered by
ageing and can reflect the effect of diet, lifestyle, or dis-
ease on cellular processes [18]. Changes in DNAm influ-
ence the relative transcription profile of the cell by
activating or inactivating gene transcription. “Methylation
age” (MA) may be a more accurate reflection of disease
than chronological age (CA). Using an ageing signature
composed by Weidner et al. to generate individual MA
[19], we hypothesised that DNAm may be altered in MPN
patients, resulting in a change in MA. Further, we hypoth-
esised that the use of an epigenetic modifier would alter
MA in PV and ET patients. Therefore, we set out to
investigate the effect of vorinostat on MA in a clinical trial
setting.Methods
Tissue culture and drug treatment
UKE-1, SET-2, and HEL cell lines were cultured in line with
standard practices. Vorinostat was solubilized in dimethyl
sulfoxide (DMSO). Specified concentrations were added to a
cell suspension obtained at 2£ 105 cells/mL. Cells were then
incubated at 37˚C for required time frames.DNAm age calculation
To validate the DNAm ageing signature previously described,
the granulocyte fraction of whole blood obtained in EDTA
from healthy volunteers was obtained by centrifugation, sepa-
ration of buffy coat, addition of phosphate-buffered saline
(PBS), and further centrifugation. DNA extraction was per-
formed using the Quick-gDNA Miniprep Kit (Zymo
Research, Irvine, CA) as per manufacturer instructions.
Bisulfite conversion of DNA was performed using the Epitect
bisulfite kit (Qiagen) as per manufacturer instructions. This
converts unmethylated cytosine to uracil, leaving methylcyto-
sine residues unaffected. The PyroMark PCR kit (Qiagen)
was used to amplify DNA for regions within ASPA, ITGA2B,
and PDE4C genes using primers with biotinylation of the 50
sequence. DNA gel electrophoresis confirmed adequate PCR
product. Pyrosequencing was undertaken using the PyroMark
Gold Q24 reagents kit (Qiagen) and PyroMark Q24
sequencer machine. DNAm levels were inserted into the epi-
genetic ageing signature previously described by Weidner
et al. [19].Clinical trial samples
Samples were available from PV and ET patients in a non-rando-
mised open label phase II multicentre study of vorinostat (EudraCT
No. 2007-005306-49). At trial enrollment, patients had consented to
the collection, storage, and analysis of additional peripheral blood
samples for use in research associated with the trial. Quantitative
analysis of JAK2 V617F was performed as previously described
[17]. Clinicohematological parameters were used to assess response
as previously described [17].
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GraphPad Prism Version 5 software was used to calculate all
statistical values including IC50, R
2, and p values using the
paired/unpaired t test as appropriate (***p < 0.001, **p <
0.01, *p < 0.05, n.s. = not significant).
Results
Validation of ageing signature
In 2014, Weidner et al. performed a comprehensive
analysis of 102 age-related CpG sites in blood [19].
They described how the measurement of DNAm levels
at CpGs within three key genes— ASPA, ITGA2B,
PDE4C—enabled the determination of a reliable MA
that reflected CA in normal individuals using an “aging
signature” calculation (Figure 1A). To ensure the age-
ing signature calculation presented in the publication
was representative of CA in normal individuals in our
hands, samples were obtained with verbal consent from
5 healthy volunteers. The mean age of the volunteers
was 39 years (range: 23−60) and included 3 females
and 2 males. The granulocyte fraction was obtained
from peripheral blood samples obtained in EDTA with
subsequent DNA extraction. Pyrosequencing of each
gene of interest was performed in turn following bisul-
fite conversion of the DNA and PCR cycling. One siteFigure 1. (A) Calculation prepared by Weidner et al. that predicted
CA in normal individuals by assessing DNAm levels within three
genes: ASPA, ITGA2B, and PDE4C. (B) Correlation of MA to CA in
healthy volunteers revealed that the final MA and CA were closely
correlated in a healthy volunteer group.of CpG methylation was analysed within ASPA, three
sites within ITGA2B, and four sites within PEDE4C.
MA was calculated for each of the volunteers using the
ageing signature calculation. Using the mean of DNAm
values at sites 1 and 3 within PDE4C, the mean of
DNAm at all sites in ITGA2B and the DNAm value for
the one site in ASPA resulted in a MA that closely
aligned with the chronological age of the volunteers as
a whole group, as illustrated in Figure 1B (r = 0.987,
confidence interval [CI]: 0.81−1.0).
Effect of vorinostat on MA in clinical trial samples
Vorinostat was tested as a therapeutic strategy in a group of
PV and ET patients as part of an investigator-initiated non-
randomised open label phase II multicentre study (EudraCT
No. 2007-005306-49). This study included 63 patients from
15 centres across Europe. Vorinostat was given at a dose of
400 mg orally once daily for 24 weeks. Response rate (RR) to
vorinostat (complete response [CR] and partial response
[PR]) on an intention-to-treat basis was 35%, with a decrease
in the incidence of splenomegaly and constitutional symp-
toms (in particular pruritus). There was, however, a high dis-
continuation rate (52%) because of side effects (most
commonly diarrhea, fatigue, and renal impairment) or lack of
response [17].
DNA samples from 22 PV and 18 ET patients from
this trial were available for research purposes. The gen-
der split was 23 female patients and 17 male patients
with a mean age of 62 years at trial entry (range: 29
−81). Time from diagnosis to trial entry was available
for all but 1 patient and was on average 347 weeks
(range: 0−1428). All patients underwent a wash-out
period before enrolment and were drug free at the time
of trial entry. Figure 2A illustrates the demographics of
the trial participants, relative JAK2 V617F allele bur-
dens, and response rates per trial criteria.
Samples originating from peripheral blood were
taken at trial enrolment prior to receipt of vorinostat
and after 3 months of therapy. In 21 of the 40 patients,
DNA was also available after 6 months of vorinostat
treatment. MA was determined for each patient at each
sample time point. A predicted MA was also generated
for each patient, using their known CA and the ratio
established in the healthy volunteer group. We were
then able to correlate MA with clinical parameters
including known CA, gender, disease group, mutational
profile, and therapeutic response.
The correlation of MA to CA at each time point is
illustrated for all patients in Figure 2B. The trend line
established in healthy volunteers allowed the patients
in whom the calculated MA was older or younger than
expected to be clearly visualized. At baseline, a trend
towards a higher than predicted MA was observed,
averaging 0.5 year older than expected for CA (range:
31.9 years younger to 49.8 years older). After 6 months
Figure 2. (A) Gender, JAK2 mutant status, and response classification for each disease category. In 66.7% (n = 6/9) of the JAK2 wild-type
patients, CALR was confirmed as the driver mutation. (B) Correlation of MA to CA in vorinostat-treated patients. Calculated MA at each time
point compared with known CA of patients with trend line as established in healthy volunteers. Patients below the line are younger than
expected for CA, whereas those above the line are older than expected for CA
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toward a lower than expected MA when compared with
CA (1.0 years younger, range: 26.2 years younger to
43.9 years older).
After the entire cohort was surveyed, each disease
group (PV and ET) was scrutinised separately. We
observed a tendency towards a higher than expected
MA at all time points in PV, whilst the opposite was
true in the ET cohort. This was despite having a simi-
lar mean CA (PV 61.8 years, range: 29−78; ET
62.6 years, range: 51−81). Amongst PV patients, the
mean MA was 58.1 years (range: 35.2−104.9) at base-
line, 57.5 years (range: 35.5−99.9) at 3 months and
50.5 years (range: 35.3−93.7) at 6 months. Amongst
ET patients mean MA was 48.7 years (range: 32.3
−74.1) at baseline, 49.6 years (range: 35.3−84.9) at 3
months, and 49.1 years (range: 36.6−66.1) at 6 months.
The difference between the groups (PV vs. ET) was
statistically significant at trial entry (5.04 years older
vs. 5.1 years younger, p = 0.01), but not after 3 months
(4.44 years older vs. 4.16 years younger) or 6 months
(1.8 years older vs. 4.0 years younger) of vorinostat
therapy. Figure 3A illustrates the delta change in age
of the entire cohort and disease groups separately. In
this way, all patients start at a baseline CA of 1.0 and
their calculated MA displayed as a ratio of CA. The
change in MA after 3 months of vorinostat was not sig-
nificant and reflected the change expected from normal
chronological ageing (mean change of +0.1 years,
range: −20.9 to +10.8). When the follow-up data onthe 21 patients who had longer-term samples available
were analysed, a significant increase in MA was noted
from baseline to 6 months (mean change: +2.8 years,
range: −5.9 to +9.4, p = 0.0036, paired Student t test).
When disease groups were analysed separately, the
change from baseline to 6 months was significant only
among ET patients (mean change: +4.2 years, range:
−0.6 to +8.9, p = 0.0021) and not within the PV group
(mean change: +1.6 years, range: −5.9 to +9.4). An
MA score was calculated by subtracting the predicted
MA from the observed MA. At baseline, this MA score
was 0.45 for the entire cohort, −5.27 for ET group,
and 5.52 for the PV group. At 6 months of therapy, the
MA score was −1.04 for the whole cohort (p = 0.002),
−4.2 for the ET group (p = 0.0013), and 1.8 for the PV
group (not significant).
MA and mutational status
An analysis of variance (ANOVA) was performed to
pursue any associations between MA and the muta-
tional spectrum seen in the cohort. This included the
presence of driver mutations (wild type or mutant
JAK2, JAK2 mutant allele burden, CALR, MPL) and
any additional cooperating mutations (ASXL1, TET2,
EZH2, DNMT3, SRSF2). A statistically significant link
between MA and JAK2 allele burden was seen. JAK2
allele burden was independently associated with MA
score at baseline using linear regression (p = 0.01).
Compared with patients with low JAK2 allele burden,
patients with high JAK2 (>60% variant allele
Figure 3. (A) Change in MA with vorinostat treatment. For entire cohort and each disease group separately, the change in MA as a ratio of CA
over time. A significant change in MA was noted from baseline to 6 months in the cohort overall and when ET patients were analysed sepa-
rately. (B) Effect of JAK2 allele burden on MA. MA at all time points of the entire cohort and each disease group, separated into those with
high JAK2 allele burden and those with low burden/wild-type JAK2. Patients with high burden were significantly older by MA at baseline and
after 3 months of therapy.
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(64.2 years vs. 44.8 years, p = 0.008) and after 3
months therapy (64.3 years vs. 44.1 years, p = 0.0002).
PV and ET patients were examined separately. PV
patients with a high JAK2 allele burden compared with
the low-burden group had a mean MA of 66.0 years
versus 46.2 years at baseline (p = 0.0149) and 61.5 years
versus 46.2 years after 3 months (p = 0.0077). Within
ET, high-burden patients compared with low burden
patients had a mean MA of 57.3 years versus 50.0 yearsat baseline (not significant) and 61.5 years versus
47.8 years after 3 months (not significant). However,
after 6 months of vorinostat therapy, this relationship
between allele burden and MA was not significant in
the overall cohort, with a mean MA in high-burden
patients of 54.7 years versus 45.8 years in the low-
allele-burden group. Significance was also lost in the
PV group with the high-burden mean MA 48.5 years
versus 43.2 years in the low -burden group. There were
insufficient remaining low- burden patients in the ET
S. McPherson et al. / Experimental Hematology 2019;79:26−34 31group to draw any conclusion. When JAK2-negative
patients were included in the low-burden group, the
results were similar across all phenotypes and time
points, with only the 3-month ET time point displaying
significance where it had not been previously.
Figure 3B illustrates these results. There was no corre-
lation between JAK2 burden at baseline and change in
MA on therapy. There was no association between
change in allele burden and MA on vorinostat treat-
ment.
We examined the effect of time to enrolment in the
study on JAK2 V617F allele burden and MA. Time
from diagnosis to enrolment was available for all but 1
patient. There was a significant association between
high allele burden and longer diagnosis to enrolment
time. Amongst the high-burden patients, mean time to
enrolment was 530 weeks (range: 0−1428) compared
with 171 weeks (range: 0−776) in the low-burden
group (p = 0.02). From this, we investigated if MA was
correlated with time to enrolment. At baseline and 3
months a positive correlation was evident (R2 = 0.1291
and 0.2344,; respectively). However, by 6 months, the
variables showed no correlation. When the MA score,
the difference between calculated and predicted MA,
was analysed, the same correlations were evident.
Therefore, following Vorinostat administration, the MA
and MA score were now independent of time to enrol-
ment.
Additional cooperating oncogenic mutations were
detected in several patients (ASXL1 n = 4/40, TET2
n = 6/40, EZH2 n = 3/40), with 3 patients having more
than one mutation. No statistically significant effect
was seen on MA or MA score in relation to these
mutations.
MA and response
MA was analysed in parallel with the known response
rates of the cohort (20% complete response [CR],
42.5% partial response [PR], and 37.5% nonresponse
[NR]). In the cohort overall, NR compared with CR
was associated with a younger MA after 6 months of
therapy (38.4 years vs. 57.8 years, p = 0.01, unpaired
t test). This evidence linking patients with a younger
MA with nonresponse was also evident separately,
within the ET patient group; NR compared with PR
was associated with a younger MA after 3 months of
therapy (41.4 years vs. 56.3 years, p = 0.0156); and NR
compared with CR was associated with a younger MA
after 6 months of therapy (38.5 years vs. 59.5 years,
p = 0.0158) (Figure 4A).
When the effect of MA score on response was
examined, further correlations were noted. Although
the cohort size was small, by 6 months, NR compared
with CR was associated with an MA younger than
that expected for CA (i.e., a negative MA score)(−11.42 years vs. +7.97 years, p = 0.0477). This was
also noted separately within the ET group, where again
NR compared to CR was associated with an MA youn-
ger than expected for CA at 6 months (−13.9 years
vs. + 5.0 years, p = 0.0161). In addition, within PV, NR
compared with PR was associated with an MA older
than expected for CA at baseline (+18.0 years vs.
−5.1 years, p = 0.0279) and after 3 months of therapy
(+16.2 years vs. −4.7 years, p = 0.0293) (Figure 4B).
Discussion
The role of epigenetic dysregulation in MPN pathogen-
esis has been increasingly defined [20]. Using an epige-
netic ageing signature based on DNAm at three genes
(ASPA, ITGA2B, PDE4C) designed specifically for
peripheral blood, which has been validated for changes
in cellular composition between individuals [19], we
set out to investigate the impact on DNAm resulting
from the use of a histone deacetylase inhibitor, vorino-
stat, in real-world clinical trial samples. DNAm is per-
haps the best described epigenetic mechanism of
transcription regulation. The effect of ageing on
DNAm levels has been referred to as the “epigenetic
clock” and is a concept that has been widely accepted
for more than 50 years [18]. The phenomenon of a
diverging epigenome landscape in aging individuals
has been associated with neoplastic diseases [21], and
DNAm changes have also been implicated in myeloid
malignancy [22]. Previous studies have reported an
observable change in DNAm patterns in chronic-phase
MPN samples compared with normal samples and a
further change during transformation to blast-phase dis-
ease [10].
In keeping with this, we have found a significant
difference in MA between PV and ET, with PV
patients exhibiting a higher than predicted MA in con-
trast to ET patients exhibiting a lower than predicted
MA. We also found that patients with a higher JAK2
V617F allele burden have an increased MA for all
patients and the PV-only cohorts. This allows us to
question the role of DNA methylation change in the
pathogenesis of the eventual MPN phenotype. Our
understanding of the determination of MPN phenotype
remains incomplete. Higher JAK2 V617F allele burdens
are associated with an emphasis of the PV phenotype
[23]. Recent work suggests that the order of acquisition
of mutations may directly affect the resulting end phe-
notype [6], whilst particular cooperating somatic muta-
tions are observed with varying frequency between
MPN phenotypes, suggesting a role in the determina-
tion. The number of co-existing somatic mutations is
also observed to be higher in primary myelofibrosis
in comparison to ET or PV [24]. In observing this
difference in DNAm between ET and PV, we have
not defined cause or effect. The older MA may be a
Figure 4. (A) At each time point, the MA of the entire cohort and each disease group separated by response (CR, PR, and NR). (B) At each
time point, the MA score of the entire cohort and each disease group separated by response (CR, PR, and NR).
32 S. McPherson et al. / Experimental Hematology 2019;79:26−34reflection of other cellular processes driving the PV
phenotype potentially directly related to the JAK2
allele burden. The association between time from diag-
nosis to enrolment with JAK2 allele burden raises the
possibility that allele burden may act as a surrogate
marker for disease duration. In JAK2 V617F-positivemurine models, there is clear exhaustion of the HSC
population [25]. It could be hypothesized that exhaus-
tion of this stem cell population in higher JAK2
allele burden or prolonged diseased settings may have
an impact on the MA of the resulting haematopoietic
progenitors.
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reflected by the differing MA observed may directly
influence the development of a particular phenotype
through regulation of gene transcription favoring a PV-
or ET-type expression profile. Future studies should
aim to differentiate these hypotheses.
Our observations of the role of vorinostat in altering
DNAm have been limited by the clinical trial design.
Unfortunately, the toxicity of the dosing regime used
in the trial resulted in a high dropout rate, with many
patients failing to complete the 6 months of treatment.
Using unpaired analysis, we observed a change in the
MA of both PV and ET patients. Compared with pre-
dicted MA, in general, PV patients behaved as might
be expected of a disease cohort; ageing older than pre-
dicted at trial entry and trended towards getting youn-
ger with therapy. In contrast, ET patients actually had
a younger than anticipated MA at trial entry and
became older on therapy. Both groups trended towards
the predicted MA calculated from our normal cohort
over the course of treatment, suggesting that there was
a normalisation of DNAm patterns resulting from vori-
nostat therapy. These results are susceptible to bias
resulting from the dropout of individuals with MA
readings at the extremes of the results, for each cohort.
When we looked at paired analysis, the significance of
the increase in MA at 6 months of therapy in the ET
cohort was maintained consistent with a modification
effect towards normal resulting from vorinostat ther-
apy. We did not observe any correlation between JAK2
allele burden at baseline and change in MA on
therapy or between the change in allele burden on ther-
apy and MA.
We have described a correlation of MA to response
in the clinical trial. Nonresponse was associated with a
younger MA after 6 months of therapy in comparison
to complete responders in the ET group. Meanwhile,
nonresponse was associated with an older MA than pre-
dicted at baseline in comparison to partial responders
in the PV group. This suggests that MA may contribute
to treatment-resistant biological phenotypes. We specu-
late that in these nonresponders, vorinostat is unable to
overcome the mechanisms driving altered methylation
patterns typical of each disease phenotype. Individuals
in whom the methylation patterns are therapeutically
manipulated towards normal demonstrate an association
with disease response rates. It will be interesting to
investigate whether this association of normalisation of
DNAm patterns with disease response occurs in the set-
ting of other effective therapies for MPN, including the
JAK inhibitors.
Conclusions
This study investigated the effect of the HDACi vori-
nostat on DNAm at three key genes (ITGA2B, ASPA,and PDE4C) which have previously been validated to
produce an epigenetic aging signature in peripheral
blood. We observed an older MA at baseline in
patients with a higher JAK2 V617F allele burden.
Patients with PV had an observed MA older than pre-
dicted, whilst patients with ET had an observed MA
younger than predicted. Therefore, DNA methylation
patterns may be reflective of, or causative of, the
resulting disease phenotype. Nonresponse in ET
patients was associated with a younger than predicted
MA after therapy in comparison to patients with a
complete response. Meanwhile in PV, nonresponse was
associated with an older than predicted MA in compari-
son to partial responders prior to therapy. This is sug-
gestive that therapeutic manipulation of the DNAm
ageing pattern of cells towards normal may be reflec-
tive of response more generally. In comparison, an
inability of vorinostat to successfully manipulate
DNAm in a number of cases reflects a tendency to
nonresponse.Acknowledgments
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